中国抗癌协会乳腺癌诊治指南与规范(2024年版)Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)doi:10.19401/j.cnki.1007-3639.2023.12.004乳腺癌,诊断,治疗,指南中国抗癌协会乳腺癌专业委员会中华医学会肿瘤学分会乳腺肿瘤学组...
1,2 In recent years, the treatment landscape of ABC has evolved dramatically with the development of novel anti-cancer agents, such as CDK (cyclin-dependent kinase) 4/6 inhibitors and ADCs (antibody-drug conjugates). Based on the Guidelines for Clinical Diagnosis and Treatment of Advanced ...
[1]H.S. Rugo, W. Jacot, E. Tokunaga, et al. Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): a detailed safety analysis of the randomized, phase 3 DESTINY-Breast04 trial. 2...
[5]NCCN Guidelines Version 3.2023 Breast Cancer [6]Moy B, Rumble RB, Come SE, et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update...
The aim of this population-based study was to evaluate the impact of regional guidelines (Piedmont guidelines, PGL) for breast cancer diagnosis and treatment on quality-of-care indicators in the Northwestern Italian region of Piedmont. Methods We included two samples of women aged 50–69 years...
Triple-negative breast cancer ranks among the most aggressive types of breast cancer, and its name is attributed to the lack of three major receptors conventionally targeted for breast cancer treatment. These include receptors for HER2 (epidermal growth factor), estrogen and progesterone. The exact ...
2. Chen Z, et al. Is HER2 ultra‑low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat. 2023 Nov;202(2):313-323. 3. Manohar P, et al. Updates in endocrine therapy for metastatic breast cancer. Cancer Biol Med. 20...
the current study is the first one in the literature that investigated the changes in the serum level of sEpCAM during cancer therapy. We showed that baseline levels of sEpCAM had no prognostic value, but a decrease in sEpCAM concentration during the treatment was observed in patients with slo...
Track 1: Breast Cancer Staging Breast cancer staging is essential to determine the extent of cancer in the body, guiding treatment decisions like chemotherapy, hormone therapy, and targeted drugs. Both medical and pathologic staging systems are utilized, with tissue samples from surgery often providing...
et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 1194–1220 (2019). Article CAS PubMed Google Scholar Burstein, H. J. et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen ...